METiS Pharmaceuticals Funding, Investors & Competitors

METiS Pharmaceuticals has raised $540M across 5 funding rounds, most recently a $148M undisclosed-stage round in May 2026.

Last METiS Pharmaceuticals funding round

$148M

Undisclosed stage · May 2026

Cumulative funding METiS Pharmaceuticals raised

$540M

across 5 funding rounds

Key investors in METiS Pharmaceuticals

  • HSG
  • 5Y Capital
  • Lightspeed China Partners
  • PICC Capital Investment Management
  • BlackRock
  • Frees Fund
  • CMB International Capital Corporation
  • Hillhouse Capital

METiS Pharmaceuticals Overview

About METiS Pharmaceuticals

METiS Pharmaceuticals, operating as Jitai Medicine, is a Shanghai-based biotechnology firm leveraging artificial intelligence, machine learning, and quantum simulation for drug discovery and delivery. The company develops programmable nucleic acid drugs, novel delivery materials, and oncology candidates through AI-optimized formulation designs.


Founded

2020

HQ

ChinaHangzhou

Status

Privately held

Customer focus

B2B

Revenue model

Subscription

METiS Pharmaceuticals Funding History

METiS Pharmaceuticals has raised a total of $540M across 5 funding rounds.

METiS Pharmaceuticals' first fundraising round was a $86M Series A in December 2021. The most recent completed round was a $148M undisclosed-stage round in May 2026.

METiS Pharmaceuticals funding rounds

METiS Pharmaceuticals funding rounds
DateStageInvestorsRaisedDeal Summary
May 2026Undisclosed stageChina Venture Capital; UBS Asset Management; BlackRock; Hillhouse Capital$148MMETiS TechBio launched its Hong Kong IPO on May 6, 2026, issuing 201 million H-shares at HKD10.5 per share to raise HKD2.11 billion (approximately US$270 million), with 5% allocated to the Hong Kong public offering and listing scheduled for May 13. The IPO secured a record US$148 million cornerstone subscription led by BlackRock with US$50 million, alongside UBS Asset Management, Mirae Asset Capital, and ORIX Corporation. The cornerstone investments represent strategic allocations by global asset managers to METiS TechBio as a core asset in Chinese AI nano-delivery, marking BlackRock's medium- to long-term commitment in the AI track and the first collective appearance of these investors in the sector. This positions METiS as the world's first publicly traded AI nano-delivery company and the largest capital signal in Hong Kong's 2026 AI drug discovery IPO market to date. METiS TechBio, founded in 2020 by Chris Lai, develops AI-driven nano-delivery drug technologies. The company raised US$58 million in Series D funding in August 2025 and has secured total funding of US$308 million across six rounds, with the latest US$56 million Series D led by PICC Capital, China Life, and Sequoia China.
Aug 2025Series DBeijing Medical and Health Industry Investment Fund (lead); Daxing District Industrial Investment Fund (lead)$56MMETiS Technologies is a Beijing-based artificial intelligence-driven pharmaceutical company founded in 2020 by MIT-trained scientists specializing in nanomaterial innovation for precision drug delivery. The company has developed three proprietary platform technologies: AiLNP for nucleic acid delivery system design, AiRNA for mRNA sequence optimization, and AiTEM for small molecule formulation design. In August 2025, METiS closed a Series D financing round of 400 million yuan (approximately $55-56 million USD) co-led by the Beijing Medical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund. The company has raised approximately $300 million in total funding across multiple rounds from prominent investors including CICC Capital, Sequoia China, China Life Equity, and PICC Capital. The Series D proceeds were allocated toward platform automation upgrades, advancement of proprietary drug pipelines, global expansion initiatives, and talent recruitment. METiS announced the advancement of its lead AI-driven formulation drug candidate through Phase III clinical trials toward NDA submission. The company also unveiled its OpenCGT platform designed to address challenges in precision nanodelivery for cell and gene therapies, targeting adoption by academic institutions, hospitals, and biotech firms. Earlier reports indicated METiS was considering a Hong Kong IPO targeting approximately $200 million in proceeds, with a previously cited valuation of $600 million as of late 2023.
Jun 2024Series CCICC Capital (lead); China Taiping Insurance$100MMETiS Pharmaceuticals, a Cambridge, Massachusetts-based biopharmaceutical company nurtured by XtalPi, raised USD 100 million in a Series C financing round led by CICC Capital in June 2024, with participation from China Taiping Insurance Group. The company focuses on AI-driven drug discovery and delivery systems, with an emphasis on optimizing pharmaceutical formulation processes through its AI-enhanced platform. The funding round brought total capital raised to USD 300 million. The company planned to use proceeds to strengthen its AI-enhanced drug delivery platform and advance its in-house development pipeline. METiS is described as a Sino-US firm operating at the intersection of artificial intelligence and biopharmaceuticals, positioning itself in the growing healthtech sector focused on AI-enabled drug optimization technologies.
Apr 2022Series BChina Life Investment Holding (lead); PICC Capital Investment Management (lead); Lightspeed China Partners; Frees Fund; CMB International Capital Corporation; 5Y Capital; Monolith Management; HSG$150MMETiS Therapeutics (also referred to as METiS Pharmaceuticals or 剂泰医药), founded in 2019 and incubated by XtalPi, develops an AI-driven platform for drug discovery, formulation optimization, and delivery systems, focusing on small molecule, nucleic acid, mRNA, and gene therapy pipelines. The company, with operations in Boston, Beijing, and Hangzhou, integrates AI for molecular dynamics simulations, LNP delivery systems exceeding industry standards by over 10 times, and multi-organ targeting capabilities. Its founding team includes US Academician Chen Hongmin, CEO Chris Lai, and top MIT scientists. In April 2022, METiS announced completion of two consecutive undisclosed-series financing rounds totaling $150 million, led by PICC Capital Investment Management (PICC PE) and China Life Private Equity Investment Holding, with participation from Sequoia Capital China, 5Y Capital, CMB International Capital Corporation (CMBI), Lightspeed China Partners, Monolith Management, and Frees Fund. China Renaissance acted as exclusive financial advisor. These rounds followed prior funding: an angel round exceeding RMB100m ($15.7m) led by Sequoia China and pre-Series A led by Lightspeed China in late 2020, and a December 2021 Series A of $86m co-led by China Life and PICC with similar investors. The company has secured multiple rounds from Source Code Capital since angel stage. The funds support advancing pipelines to clinical trials starting in 2023, patent applications for key technologies, licensing deals for early-stage assets, pipeline expansion beyond liver targets, and partnerships with large pharmaceutical companies and academia for first-in-class and best-in-class drugs in small molecules and nucleic acids. METiS emerged from stealth with the Series A to push clinic entry in 2022 and expand into CRISPR and gene therapy.
Dec 2021Series AChina Life Insurance (lead); PICC Capital Investment Management (lead); Lightspeed China Partners; Fortune Capital; 5Y Capital; HSG; CMBI Zhaoxin Wuji Fund$86MMETiS Pharmaceuticals (also referred to as METiS Therapeutics) is a biopharma company based in Cambridge, Massachusetts, with significant operations in China, developing AI-driven medicines for serious diseases using a proprietary predictive AI platform that leverages machine learning and quantum simulation to optimize drug formulation, discovery, and delivery for small-molecule, RNA, and later gene therapy candidates. The company launched with an $86 million Series A financing round announced on December 7, 2021, led by China Life Insurance and PICC Capital Investment Management (PICC PE), with participation from Lightspeed China Partners (also called Sequoia Capital China or Lightspeed in some reports), 5Y Capital, and other institutional investors including Fortune Capital, CMBI Zhaoxin Wuji Fund, and HSG. The funds were earmarked to support a 2022 clinical trial for its lead candidate, pipeline expansion beyond liver targets, licensing of early-stage assets, U.S. team growth from about 70 employees (mostly in China), and platform enhancements including CRISPR and gene therapy. The company demonstrated early traction through partnerships, such as a 2023 licensing deal with Ardelyx yielding a $750,000 upfront payment plus up to $243 million in milestones and royalties, and collaborations with Zhejiang Huahai Pharmaceutical, alongside a pipeline of 10 drug candidates and 26 patents. METiS addresses gaps in AI-driven drug delivery and formulation, a market projected to grow significantly, positioning it amid the AI drug discovery boom with investors betting on its platform to accelerate preclinical operations and reduce development costs. Post-Series A milestones included joining the Roche Accelerator in May 2022 and appointing Hongming Chen as President and Head of R&D in January 2022, with subsequent rounds raising total funding over $250 million by mid-2024 and plans for a $200 million Hong Kong IPO targeting a doubled valuation.

Who has invested in METiS Pharmaceuticals?

19 investors have backed METiS Pharmaceuticals across its funding rounds, including HSG, 5Y Capital, Lightspeed China Partners, PICC Capital Investment Management, BlackRock and Frees Fund.

Lead investors include Beijing Medical and Health Industry Investment Fund, Daxing District Industrial Investment Fund, CICC Capital, China Life Investment Holding, PICC Capital Investment Management and 1 other investor.


METiS Pharmaceuticals Investors

Investors in METiS Pharmaceuticals by funding rounds participated
InvestorHQRoundsRoleFirst check
Lightspeed China PartnersChinaShanghai2ParticipantDec 2021
5Y CapitalChinaChina2ParticipantDec 2021
HSGHong KongHong Kong2ParticipantDec 2021
PICC Capital Investment ManagementChinaShanghai2LeadDec 2021
Frees FundChinaBeijing1ParticipantApr 2022
Fortune CapitalUnited StatesMiami, FL1ParticipantDec 2021
China Venture CapitalChinaBeijing1ParticipantMay 2026
Daxing District Industrial Investment FundChinaChina1LeadAug 2025
China Taiping InsuranceHong KongHong Kong1ParticipantJun 2024
UBS Asset ManagementUnited KingdomLondon1ParticipantMay 2026
BlackRockUnited StatesUnited States1ParticipantMay 2026
CICC CapitalChinaBeijing1LeadJun 2024
China Life InsuranceChinaBeijing1LeadDec 2021

This data is available for Pro users. Sign up to see all 19 METiS Pharmaceuticals investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

METiS Pharmaceuticals Competitors

METiS Pharmaceuticals competitors include listed companies like SAP and Snowflake, and private ones like Astromech, Chai Discovery, Quantum Systems and SandboxAQ.

Public and private companies comparable to METiS Pharmaceuticals
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
AstromechUnited StatesUnited StatesPrivate--$3.8B-
Chai DiscoveryUnited StatesSan Francisco, CAPrivate$48M-$3.8B-
Quantum SystemsGermanyGilchingPrivate$330M-$8B24.2x
SandboxAQUnited StatesSan Francisco, CAPrivate--$5.8B-
SAPGermanyGermanyPublicly listed$42B$13B$248B5.4x
SnowflakeUnited StatesUnited StatesPublicly listed$4.7B($1.3B)$119B21.0x

METiS Pharmaceuticals Public Comps

METiS Pharmaceuticals is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, CrowdStrike, SAP and Amgen.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Eli Lilly$65B$28B16.5x13.1x38.7x27.0x
Johnson & Johnson$94B$40B7.2x6.8x17.0x18.3x
AbbVie$61B$17B8.7x8.1x30.6x17.6x
Merck$65B$28B6.3x6.2x14.7x21.0x
Roche$77B$26B5.0x4.9x14.6x12.4x
Novartis$57B$22B5.5x5.5x14.2x13.3x
AstraZeneca$59B$19B4.8x4.5x14.6x12.7x
CrowdStrike$4.8B($12M)51.4x44.5x(19816.2x)151.0x

This data is available for Pro users. Sign up to see all METiS Pharmaceuticals competitors and their valuation data.

Start Free Trial

Common questions about METiS Pharmaceuticals

When was METiS Pharmaceuticals founded?METiS Pharmaceuticals was founded in 2020.
Where is METiS Pharmaceuticals headquartered?METiS Pharmaceuticals is headquartered in Hangzhou, China.
Is METiS Pharmaceuticals publicly listed?No, METiS Pharmaceuticals is a private, VC-backed company.
How much funding has METiS Pharmaceuticals raised?METiS Pharmaceuticals has raised $540M across 5 funding rounds.
What was METiS Pharmaceuticals' last funding round?METiS Pharmaceuticals' last funding round was a $148M undisclosed-stage round in May 2026.
Who are METiS Pharmaceuticals' investors?METiS Pharmaceuticals' investors include Lightspeed China Partners, 5Y Capital, HSG, PICC Capital Investment Management, Frees Fund, Fortune Capital, China Venture Capital, Daxing District Industrial Investment Fund, China Taiping Insurance, UBS Asset Management and 9 others.
Which companies are comparable to METiS Pharmaceuticals?Companies comparable to METiS Pharmaceuticals include Astromech, Chai Discovery, Quantum Systems, SandboxAQ, SAP and Snowflake.

See companies similar to METiS Pharmaceuticals

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial